Literature DB >> 3625478

Kinetics of ajmaline disposition and pharmacologic response in beagle dogs.

M Yasuhara, Y Hashimoto, K Okumura, R Hori, T Sakurai, C Kawai.   

Abstract

Pharmacokinetics and pharmacodynamics of ajmaline were studied in four healthy dogs after intravenous administration of the drug at the infusion rate of 1.0 mg/min for 45 min. Ajmaline exhibited a saturable binding to plasma protein. One kind of binding site was found in the range of observed drug concentrations and its binding capacity showed nearly threefold interindividual difference. The time course of ajmaline concentration in whole blood Cb could be described by the two-compartment open model and the unbound concentration of ajmaline in plasma Pf was estimated from Cb by using the hematocrit value and the parameters of plasma protein binding and erythrocyte partitioning. The pharmacologic responses to ajmaline were assessed by recording ECG, and the changes in PQ and QRS interval were studied in relation to ajmaline disposition. When ECG changes were related to the ajmaline concentration, a significant degree of hysteresis was observed. The relationship between the unbound drug concentration and the pharmacologic effect was analyzed by a combined pharmacokinetic-pharmacodynamic model, where the hypothetical effect compartment is connected to the Pf in the central compartment by a first-order process. This model allows estimation of the changes in PQ and QRS intervals after intravenous administration of ajmaline. By comparing the drug effect on PQ and QRS intervals, it was suggested that ajmaline distributes to the atrial and the ventricular tissue in a similar degree and causes a reduction in the conduction rate in both sites with similar activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3625478     DOI: 10.1007/BF01062938

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  24 in total

1.  Cardiovascular effects and blood concentrations of ajmaline and its 17-monochloroacetate ester in cats.

Authors:  B Spilker; L Shargel; R F Koss; H Minatoya
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-07

2.  [ELECTROPHYSIOLOGICAL STUDIES ON THE EFFECT OF AJMALINE ON CONDUCTION FIBERS].

Authors:  B PILLAT; P HEISTRACHER
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1964-02-13

3.  [On the pharmacology of ajmaline].

Authors:  H SCHMITT H SCHMITT
Journal:  Arch Int Pharmacodyn Ther       Date:  1960-08-01

4.  [On the mechanism of action of ajmaline].

Authors:  G KUSCHINSKY; H REUTER
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1961

5.  The effects of ajmaline in experimental and clinical arrhythmias and their relation to some electrophysiological parameters of the heart.

Authors:  R Bojorges; G Pastelin; S Sanchez-Perez; R Mendez; E Kabela
Journal:  J Pharmacol Exp Ther       Date:  1975-04       Impact factor: 4.030

6.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

7.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

8.  Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.

Authors:  M Thibonnier; N H Holford; R A Upton; C D Blume; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

View more
  4 in total

1.  Effect of ajmaline on sustained ventricular tachycardia induced by programmed electrical stimulation in conscious dogs after myocardial infarction.

Authors:  H Todt; G Krumpl; N Zojer; K Krejcy; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

2.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

3.  Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism.

Authors:  Y Hashimoto; M Yasuhara; A Kamiya; K Okumura; R Hori
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

Review 4.  The Mechanism of Ajmaline and Thus Brugada Syndrome: Not Only the Sodium Channel!

Authors:  Michelle M Monasky; Emanuele Micaglio; Sara D'Imperio; Carlo Pappone
Journal:  Front Cardiovasc Med       Date:  2021-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.